AI infectious disease startups face hurdles to investor returns, Cortado Ventures says
XLV•AI-driven infectious disease startups face uncertain returns despite opportunities in pathogen detection, outbreak forecasting and antibiotic discovery. Funding has returned to historical levels from $2.9 billion in the first quarter of 2020, while government-customer dependence, long development timelines and clinical adoption hurdles complicate returns.
1. Investment hurdles
AI-driven infectious disease startups face uncertain investment returns despite opportunities in pathogen detection, outbreak forecasting and antibiotic discovery. Infectious disease funding has returned to historical levels from $2.9 billion in the first quarter of 2020 as investor focus shifted toward oncology and AI platforms.
2. Market and development risks
Outbreak forecasting could offer substantial public savings, but reliance on government customers limits the market and complicates valuation. Antibiotic developers face long timelines and high clinical trial costs, leaving nontraditional capital to absorb much of the early risk. Real-world accuracy losses, opaque predictions and liability uncertainty could also hinder clinical adoption and investor returns.
